Theravance Biopharma, Inc. (NASDAQ:TBPH) is one of the most undervalued biotech stocks to buy right now. B. Riley lifted the price target on Theravance Biopharma, Inc. (NASDAQ:TBPH) to $17 from $14 on April 7, reiterating a Neutral rating on the shares. The firm told investors that the final generic settlement with MannKind Corporation locks exclusivity through April 2039, “removing the last overhang on a clean single-asset story”.
In its financial and operational results for fiscal Q4 and full year 2025, Theravance Biopharma, Inc. stated that the company ended the year “on a positive note from a financial perspective”, attaining “another record quarter of non-GAAP profitability, hitting a new all-time high for YUPELRI® brand-level profitability, and reaching $75 million in key sales-based milestones.” Management stated that the results highlight the durability and strength of the company’s commercial asset, YUPELRI®, as well as the strength of its balance sheet. Theravance Biopharma, Inc. also reported that the full-year 2025 TRELEGY net sales, reported by GSK, were $3.9 billion, up 12% year-over-year, which triggered a $50 million milestone payment.
Theravance Biopharma, Inc. is a biopharmaceutical company involved in the discovery, research, development, and commercialization of respiratory medicines. The company’s operations are divided into the following geographical segments: the U.S. and Europe.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
